Effects of doxorubicin combined with cisplatin on efficacy, survival rate and toxicity in cervical cancer patients with radiotherapy
-
摘要: 目的 分析宫颈癌放疗患者中联合应用多柔比星与顺铂化疗的效果以及临床价值。 方法 选取本院收治的120例宫颈癌患者为研究对象,将所有患者等分为治疗组(接受多柔比星与顺铂联合化疗)和常规组(接受顺铂化疗)。比较2组治疗前后生化指标、治疗效果、生存率以及毒副作用。 结果 与常规组比较,治疗组疾病控制率、Ki-67蛋白表达水平、局部复发率显著较低,细胞内脆性组胺三联体(FHIT)蛋白、B淋巴细胞瘤-2相关X蛋白(Bax)蛋白表达水平显著较高(P<0.05); 2组半年生存率、远处转移率、毒副作用发生率比较,差异无统计学意义(P>0.05); 治疗组局部复发率较常规组显著更低(P<0.05)。 结论 多柔比星与顺铂联合应用于宫颈癌患者化疗中能显著提高治疗效果,且毒副作用较小,患者生存率高。Abstract: Objective To analyze the effect and clinical value of doxorubicin and cisplatin in combination for chemotherapy in cervical cancer patients with radiotherapy. Methods A total of 120 patients with cervical cancer were selected, and equally divided into treatment group(receiving doxorubicin and cisplatin in combination for chemotherapy)and routine group(receiving cisplatin for chemotherapy). The biochemical indicators, treatment effects, survival rates and toxic and side effects of two groups were compared before and after treatment. Results Compared with the conventional group, the disease control rate, Ki-67 protein expression level, and local recurrence rate were significantly lower, and expression levels of fragile intracellular histamine triplet(FHIT)protein and Bcl-2 associated protein X(Bax)in the treatment group were significantly higher(P<0.05); there were no differences in the half-year survival rate, distant metastasis rate, and incidence of toxic and side effects between the two groups(P>0.05). The local recurrence rate in the treatment group was significantly lower than that in the conventional group(P<0.05). Conclusion Doxorubicin and cisplatin in combination as chemotherapy for patients with cervical cancer can significantly improve treatment effect, and has less toxic and side effects.
-
Keywords:
- cisplatin /
- doxorubicin /
- drug combinations /
- cervical cancer /
- survival rate /
- toxic and side effects
-
-
覃杏幸, 莫永华, 刘桂玉. 多柔比星联合顺铂化疗对宫颈癌放疗患者的疗效及对相关基因蛋白表达的影响[J]. 广西医学, 2016, 38(9): 1256-1259. 向安玲, 庄瑞春, 彭玲. 紫杉醇联合顺铂新辅助化疗对晚期宫颈癌患者淋巴结转移率及远期预后的影响[J]. 河北医学, 2019, 25(2): 219-223. 李莉, 李根, 梁华, 等. 低剂量顺铂联合5-氟尿嘧啶与顺铂单药用于中晚期宫颈癌同期放化疗中的对比研究[J]. 中国医药导报, 2016, 13(6): 119-122. 童武松, 王松林, 潘金华. 顺铂联合紫杉醇同步放化疗对中晚期宫颈癌患者免疫功能及血清CY-FRA21-1、SCC-Ag的影响[J]. 海南医学院学报, 2016, 22(23): 2866-2868. 陆国权, 周晓红, 陈红, 等. 多西他赛联合顺铂化疗同步放疗治疗中晚期宫颈癌效果观察[J]. 山东医药, 2016, 56(38): 83-84. 李芷茹, 曾守群, 李超, 等. 紫杉醇和顺铂联合调强放疗治疗宫颈癌的临床疗效[J]. 中国妇幼健康研究, 2018, 29(7): 929-932. 王芳芳, 廖思辉, 陈运强, 等. 不同化疗药物联合同期放疗治疗局部中晚期宫颈癌的临床疗效及不良反应观察[J]. 广西医科大学学报, 2019, 22(3): 412-415. 唐滟, 袁亚维, 彭培清, 等. 调强放疗同步两种方案化疗治疗宫颈癌近期疗效及不良反应对比分析[J]. 现代肿瘤医学, 2016, 24(22): 3611-3615. 祖里皮亚汗·库热西, 丁岩, 陈志芳. 中晚期宫颈鳞状细胞癌放化疗综合治疗的临床进展[J]. 国际妇产科学杂志, 2017, 44(5): 485-489. 宋前燕, 毛熙光. BGJ398与顺铂单独或联合作用对宫颈癌Hela细胞增殖、凋亡、侵袭的影响及其机制研究[J]. 中国医刊, 2019, 54(3): 303-309. 王群, 胡卫红, 胡乃刚. 多柔比星灌注治疗对行TURBT术后浅表性膀胱癌患者临床疗效及相关指标的影响[J]. 中国药房, 2017, 28(36): 5091-5094. 呼改凤, 付海霞, 马继芳, 等. 蒽环类药物对早期乳腺癌术后患者心脏毒性影响的临床研究[J]. 中华心血管病杂志, 2018, 46(12): 987-992. 董仙萍, 王健, 杨冬梅, 等. 宫颈上皮内瘤变及宫颈癌组织中DLC-1、BMI-1、C-myc、FHIT的表达及意义[J]. 山东医药, 2018, 58(14): 75-78. -
期刊类型引用(1)
1. 邱换换，葛高琪，郭瑾，刘建芳，路亚婉. 基于主观整体营养评估量表评分的营养干预对结直肠癌患者化疗期营养摄入和生活质量的影响. 国际医药卫生导报. 2025(01): 136-140 . 
百度学术
其他类型引用(0)
计量
- 文章访问数: 392
- HTML全文浏览量: 94
- PDF下载量: 15
- 被引次数: 1
下载:
苏公网安备 32100302010246号